Autoimmune Multi Biomarker Test for Rheumatoid Arthritis (Vectra® DA)
Vectra® DA is a blood test that measures the concentration of 12 different biomarkers (serum proteins) associated with rheumatoid arthritis (RA) activity. A proprietary algorithm is used to analyze the biomarker levels and generate a score ranging from 1-100 that reflects the level of RA disease activity. The biomarkers measured by Vectra DA include the most common proteins that are involved in inflammation, joint destruction, and cartilage degeneration. The 12 biomarkers assessed by this test are as follows: VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, MMP-1, YKL-40, Leptin, Resistin, SAA, CRP. Analysis of these 12 biomarkers together generates the Vectra® DA test score, which provides information about the likelihood of future joint damage and the level of RA disease activity.
Because Vectra DA helps predict joint damage, it will aid healthcare providers in adjusting treatment plans to prevent or minimize joint damage and erosion. In addition, Vectra DA test can be used to monitor the effectiveness of RA treatment over time. If the test score improves, it suggests that the treatment is effective. Conversely, if the test score worsens, it may be an indication that the treatment needs to be adjusted. Therefore, Vectra DA, in conjunction with symptoms, physical exam findings, and imaging studies, is used to assess disease activity and guide treatment decisions rather than diagnosis.
- To determine the level of disease activity in patients with rheumatoid arthritis
- To guide treatment decisions and monitor the effectiveness of therapy
- Disease management and therapy adjustment based on the score changes
Score <29 is considered as normal range. Note: the score depends on the results of 12 biomarkers measured from serum. Each biomarker has a normal range.
Serum (SST).
Stability
- Ambient: 3 days
- Refrigerated: 7-14 days
- Frozen: 1 year
- Curr Med Res Opin. 2019 Sep;35(9):1483-1493. [PMID: 30777458]
- Arthritis Res Ther. 2021 Jan 4;23(1):1. [PMID: 33397438]
- Clin Rheumatol. 2019 Feb;38(2):437-445. [PMID: 30159791]
- J Rheumatol. 2019 Mar;46(3):237-244. [PMID: 30442830]
- Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-29-34. [PMID: 25365086]
- Expert Rev Clin Immunol. 2019 Feb;15(2):135-145. [PMID: 30556738]